Muscle Wasting Disorders Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The muscle wasting disorders market size has grown rapidly in recent years. It will grow from $15.06 billion in 2024 to $17.54 billion in 2025 at a compound annual growth rate (CAGR) of 16.5%. The growth in the historic period can be attributed to increasing aging population, rising incidence of chronic diseases, advancements in research and development, increased awareness of early diagnosis, emerging therapeutic approaches.

The muscle wasting disorders market size is expected to see rapid growth in the next few years. It will grow to $29.67 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to regulatory support, patient advocacy initiatives, healthcare infrastructure development, globalization of clinical trials, personalized medicine approaches. Major trends in the forecast period include telemedicine adoption, technological advancements in diagnostics, product innovation, collaborations and partnerships, advancements in therapeutics, research on molecular mechanisms, biopharmaceutical innovation.

The anticipated rise in adherence to a sedentary lifestyle is poised to drive the growth of the muscle wasting disorders market in the future. A sedentary lifestyle, characterized by limited physical activity and minimal exercise, has been linked to negative impacts on muscle function. This can result in a reduction in muscle strength and endurance, contributing to muscle wasting disorders. In 2022, the World Health Organization reported that over 80% of adolescents and 27% of adults did not meet recommended physical activity levels. This trend towards a sedentary lifestyle is a significant factor propelling the expansion of the muscle wasting disorders market.

Key players in the muscle wasting disorders market are actively developing innovative products, particularly novel gene therapies, to better address the needs of patients with muscle wasting disorders. Novel gene therapy involves manipulating gene expression or altering the biological properties of living cells to achieve therapeutic effects. For example, Sarepta Therapeutics, a US-based biotechnology company, introduced Elevidys in June 2023. Elevidys, the first gene therapy approved by the U.S. FDA for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 to 5, utilizes recombinant gene therapy to deliver a gene leading to a shortened protein with selected domains of the dystrophin protein. The therapy is administered as a single intravenous infusion.

In September 2023, Biogen Inc., a US-based biotechnology company, acquired Reata Pharmaceuticals Inc. for $7.3 billion. This acquisition is expected to enhance Biogen's rare disease portfolio, specifically addressing Friedreich's ataxia - a genetic, progressive, and debilitating neuromuscular disorder affecting the nervous system and muscles. Reata Pharmaceuticals Inc., the acquired US-based pharmaceutical company, focuses on developing therapeutics for neuromuscular disorders and muscle wasting disorders, further solidifying Biogen's position in the market.

Major companies operating in the muscle wasting disorders market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Roche Holding AG, Novartis AG, Sanofi, GlaxoSmithKline (GSK), Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Acceleron Pharma Inc., Biogen Inc., Santhera Pharmaceuticals Holding AG, Mitsubishi Tanabe Pharma, Nippon Shinyaku Co. Ltd. (NS Pharma, Inc.), Sarepta Therapeutics Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Axogen, Inc., FibroGen Inc., Cytokinetics Incorporated, Italfarmaco S.p.A., Scholar Rock, Bellerophon Therapeutics, Akashi Therapeutics, aTyr Pharma, Metabolic Solutions Development Company, Synaptogenix, MyoKardia, Inc., MyoTherix Inc.

North America was the largest region in the muscle wasting disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle wasting disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the muscle wasting disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The muscle wasting disorders market consists of revenues earned by entities by providing services such as diagnostic services, medical services, support services and community services. The market value includes the value of related goods sold by the service provider or included within the service offering. The muscle wasting disorders market also includes sales of anabolic steroids, growth hormone, enobosarm and bimagrumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Muscle wasting disorders, also known as muscle atrophy or muscle wasting, encompass a range of conditions marked by the gradual reduction of muscle mass and strength. This phenomenon can be attributed to various factors, such as lack of use, aging, malnutrition, neurodegenerative diseases, and specific medical conditions.

Primary treatments for muscle wasting disorders include medications, physical therapy, nutritional therapy, surgery, gene therapy, and various other interventions. Medications for muscle wasting disorders are specifically designed to address conditions such as sarcopenia, cachexia, and muscular dystrophy. The goal of these medications is to enhance muscle mass and improve overall muscle function. They find application in the treatment of conditions such as muscular dystrophy, amyotrophic lateral sclerosis (ALS), and others, being utilized by hospitals, rehabilitation centers, specialty clinics, and other end-users.

The muscle wasting disorders market research report is one of a series of new reports that provides muscle wasting disorders market statistics, including muscle wasting disorders industry global market size, regional shares, competitors with a muscle wasting disorders market share, detailed muscle wasting disorders market segments, market trends and opportunities, and any further data you may need to thrive in the muscle wasting disorders industry. This muscle wasting disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.